[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354801-105":59,"doc-detail-354801-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","from-in-silico-prediction-to-experimental-validation-identification-of-drugs-and-novel-synergistic-combinations-that-inhibit-growth-of-inflammatory-breast-cancer-cells","From in silico prediction to experimental validation - Identification of drugs and novel synergistic combinations that inhibit growth of inflammatory breast cancer cells","","Drug repurposing can accelerate therapeutic candidate discovery for rare, highly aggressive inflammatory breast cancer (IBC) where treatment options remain limited. An experimental validation study tests compounds previously identified via Literature Wide Association Studies (LWAS) and Gene Reversal Rate (GRR). Orthogonal viability assays across 2D IBC and non-IBC models show higher success for LWAS in SUM149 (70%) than GRR (38%). Combination screening in 2D and 3D spheroids finds synergistic pairs targeting IGF-1R/EGFR and PI3K-Akt-mTOR pathway crosstalk. Western blotting demonstrates reduced phosphorylation of key proteins, migration is decreased, and RNA-Seq confirms GRR combinations reverse the IBC gene expression signature (IBC-GES), supporting computational repurposing strategies for overcoming resistance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/from-in-silico-prediction-to-experimental-validation-identification-of-drugs-and-novel-synergistic-combinations-that-inhibit-growth-of-inflammatory-breast-cancer-cells/354801/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/from-in-silico-prediction-to-experimental-validation-identification-of-drugs-and-novel-synergistic-combinations-that-inhibit-growth-of-inflammatory-breast-cancer-cells/354801.png","ImageObject",300,407,{"name":92,"@type":93},"MrHarris58","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What computational approaches guided the candidate compounds in this study?","Question",{"text":112,"@type":113},"The study used Literature Wide Association Studies (LWAS) and Gene Reversal Rate (GRR) to identify candidate compounds for experimental testing.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the candidates validated experimentally?",{"text":117,"@type":113},"Compounds were evaluated using orthogonal cell viability assays in 2D IBC and non-IBC models, followed by systematic combination screening in both 2D and 3D SUM149 spheroid systems.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence suggests the identified combinations are synergistic and effective?",{"text":121,"@type":113},"The combinations produced high synergy scores across reference models, decreased phosphorylation of key signaling proteins by western blotting, reduced cell migration in wound healing assays, and reversed the IBC gene expression signature (IBC-GES) in RNA-Seq analysis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354801,1790189147,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":24,"preview_urls":146},687212988360,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","OPEN ACCESS  \nCitation: Salim EA, Ji X, Tarpley M, Dixon MS, Zheng W, Scott JE, et al. (2026)  \nFrom in silico prediction to experimental validation: Identification of drugs and novel synergistic combinations that inhibit growth of inflammatory breast cancer cells. PLoS One 21(9): e0339543. [https://doi.org/10.1371/](https://doi.org/10.1371/)[ ](https://doi.org/10.1371/)[journal.pone.0339543](journal.pone.0339543)  \nEditor: Divijendra Natha Reddy Sirigiri, BMSCE:  \nBMS College of Engineering, INDIA Received: December 8, 2025  \nAccepted: August 11, 2026  \nPublished: September 16, 2026  \nCopyright: © 2026 Salim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nData availability statement: All relevant data are within the paper and its supporting  information files. Original images for blots are in the S1 Raw Images file. The RNA-Seq data generated and used in this study are openly  \nRESEARCH ARTICLE  \nFrom in silico prediction to experimental validation: Identification of drugs and novel synergistic combinations that inhibit growth of inflammatory breast cancer cells  \nEsraa A. Salim1, Xiaojia Ji1, Michael Tarpley1, Maria S. Dixon1, Weifan Zheng1,2, John E. Scott1,2*, Kevin P. Williams1,2*  \n1 Biomanufacturing Research Institute and Technology Enterprise, North Carolina Central University, Durham, North Carolina, United States of America, 2 Department of Pharmaceutical Sciences, North Carolina Central University, Durham, North Carolina, United States of America  \n* [kpwilliams@nccu.edu](kpwilliams@nccu.edu) (KPW); [j](jscott@nccu.edu)[scott@nccu.edu](jscott@nccu.edu) (JES)  \nAbstract  \nDrug repurposing can accelerate the identification of novel therapeutic candidates for rare cancers such as inflammatory breast cancer (IBC), an aggressive type with limited therapeutic options. Here, we report an experimental validation study of compounds previously identified through two computational approaches: Literature Wide Association Studies (LWAS) and Gene Reversal Rate (GRR) . Candidate compounds were tested using orthogonal cell viability assays in 2D models across IBC and nonIBC cell lines. In the SUM149 IBC cell line, repurposed compounds predicted from LWAS achieved a 70% success rate, with several showing nanomolar potency, while those predicted from GRR showed a 38% success rate. Through systematic combination screening in both 2D and 3D-spheroid SUM149 models, we identified novel synergistic compound pairs targeting crosstalk between IGF-1R, EGFR and PI3K/ Akt/mTOR pathways, with high synergy scores across multiple reference models. Using these combinations, western blott analysis revealed significant suppression in the phosphorylation of key signaling proteins and downstream effectors, while wound healing assays showed reduced cell migration with some combination treatments, suggesting effective pathway inhibition. To further validate these findings at the transcriptional level, RNA-Seq analysis in SUM149 cells confirmed that the GRR drug combinations significantly reversed the IBC gene expression signature (IBC-GES) and identified several clinically relevant genes whose expression was significantly altered. Together, these findings validate our computational predictions and identify candidate combination strategies that may help address therapeutic resistance in IBC. This integrated computational-experimental approach establishes a pipeline for systematic drug repurposing and highlights novel therapeutic combinations for further investigation.  \nPLOS One | [https://doi.org/10.1371/journal.pone.0339543](https://doi.org/10.1371/journal.pone.0339543) September 16, 2026 1 / 44  \navailable in Gene Expression Omnibus at: [https://www.ncbi.nlm.nih.gov/geo/](https://www.ncbi.nlm.nih.gov/geo/ reference)[ reference](https://www.ncbi.nlm.nih.gov/g","cbCaii5P40OqyQ14","https://ap.wps.com/l/cbCaii5P40OqyQ14","pdf",6342771,44,"English","# Abstract\n# Introduction","[{\"question\":\"What computational approaches guided the candidate compounds in this study?\",\"answer\":\"The study used Literature Wide Association Studies (LWAS) and Gene Reversal Rate (GRR) to identify candidate compounds for experimental testing.\"},{\"question\":\"How were the candidates validated experimentally?\",\"answer\":\"Compounds were evaluated using orthogonal cell viability assays in 2D IBC and non-IBC models, followed by systematic combination screening in both 2D and 3D SUM149 spheroid systems.\"},{\"question\":\"What evidence suggests the identified combinations are synergistic and effective?\",\"answer\":\"The combinations produced high synergy scores across reference models, decreased phosphorylation of key signaling proteins by western blotting, reduced cell migration in wound healing assays, and reversed the IBC gene expression signature (IBC-GES) in RNA-Seq analysis.\"}]","From in silico prediction to experimental validation - Identification of drugs and novel synergistic combinations that inhibit growth of inflammatory breast cancer cells | PDF",1790114060,111,[147,151,155,159,163],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6092eb6a3bb7e6ae5f81af4d6d5bdb8.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b5fd2e902cc1433308c4857d56b93497.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/541f4f4e4a30a5e9666d968a92f28c1a.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cedcc96f112e41edc562a40a3ae12535.webp",980,1268,{"page_no":24,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d2d456fe096258d17e1ccb9d5f40c4b2.webp",979,1267]